Effects of growth hormone on circulating cytokine network, and left ventricular contractile performance and geometry in patients with idiopathic dilated cardiomyopathy

Adamopoulos, Stamatis; Parissis, John; Paraskevaidis, Ioannis; Karatzas, Dimitrios; Livanis, Efthimios; Georgiadis, Michael C.; Karavolias, George; Mitropoulos, Dimitrios; Degiannis, Dimitrios; Kremastinos, Dimitrios Th.

doi:10.1016/s0195-668x(03)00480-9

Cited by 78 publications

(49 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Analysis of the heart by echocardiography and equilibrium radionuclide angiography confirmed treatment-related improvements in structure and function [6, 21]. These observations strongly indicate a direct or indirect effect of GH on cardiac contractility, which may have contributed to improvements in exercise capacity and performance observed in patients receiving GH replacement therapy [24, 30]. …”

Section: Cardiac Contractilitymentioning

confidence: 88%

“…Pre-clinical and clinical studies have indicated that GHD can have an adverse effect on the contractility of cardiac muscle [29, 30]. A study by Longobardi et al (1998) also reported that patients with both adult- and childhood-onset GHD present a reduced cardiac ejection fraction compared with control subjects [4]; in particular, exercise was found to reduce ejection fraction in GH-deficient patients, whereas it was increased in healthy subjects [4].…”

Section: Cardiac Contractilitymentioning

confidence: 99%

“…In a study by Adamopoulos and colleagues [30], significant reductions in circulating levels of tumour necrosis factor alpha and interleukin-6 cytokines followed GH replacement therapy, and were associated with improved left ventricular contractile performance and a significant increase in left ventricular posterior wall thickness. In addition, reduced levels of a number of soluble adhesion molecules, including granulocyte-macrophage colony-stimulating factor receptor (GM-CSFR), intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) were reported [30]. These findings suggest that GH may have an important therapeutic role in the management of idiopathic dilated cardiomyopathy [30].…”

Section: Cardiac Contractilitymentioning

confidence: 99%

“…In addition, reduced levels of a number of soluble adhesion molecules, including granulocyte-macrophage colony-stimulating factor receptor (GM-CSFR), intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) were reported [30]. These findings suggest that GH may have an important therapeutic role in the management of idiopathic dilated cardiomyopathy [30]. …”

Section: Cardiac Contractilitymentioning

confidence: 99%

See 3 more Smart Citations

Cardiovascular Disease and Risk Factors: The Role of Growth Hormone

Isgaard

2004

Horm Res Paediatr

View full text Add to dashboard Cite

Clinical studies in patients with acromegaly have shown that growth hormone (GH) exerts both short- and long-term effects on the structure and function of the heart. Moreover, chronic growth hormone deficiency (GHD) has been associated with impaired cardiac performance, low heart rate and impaired left ventricular systolic function. Exercise capacity in patients with GHD is significantly reduced and in some severely affected individuals, dilated cardiomyopathy and heart failure has been reported. GHD has also been associated with a number of risk factors for cardiovascular disease. Altered lipoprotein metabolism and elevated fibrinogen and plasminogen activator inhibitor-1 activity are associated with GHD, and the risk of hypertension is increased in GH-deficient men. Subcutaneous and intra-abdominal fat mass have also been found to be abnormally high in these patients. These effects may contribute to an increased risk of death from cardiovascular disease. GH is therefore an important factor in the development and function of the cardiovascular system. In this paper, the effects of GH on the physiological mechanisms of the cardiovascular system are discussed, including the effect of GHD on cardiovascular disease risk. We will also discuss the effects of long-term GH replacement therapy in this patient population.

show abstract

Section: Cardiac Contractilitymentioning

confidence: 88%

Section: Cardiac Contractilitymentioning

confidence: 99%

Section: Cardiac Contractilitymentioning

confidence: 99%

Section: Cardiac Contractilitymentioning

confidence: 99%

See 2 more Smart Citations

Cardiovascular Disease and Risk Factors: The Role of Growth Hormone

Isgaard

2004

Horm Res Paediatr

View full text Add to dashboard Cite

show abstract

“…Adamopoulos S. и соавт. [1] предложили еще один механизм, за счет которого ГР может быть полезным при лечении ХСН. В рандомизированном перекрестном исследовании с участием 12 пациентов с ДКМП 3-месячный курс применения ГР вызывал уменьшение уровня провоспалительных цитокинов в крови, а также таких маркеров повреждения, как фак-тор некроза опухолей (TNF-a), интерлейкин-6 (IL-6), гранулоцит-макрофаг-колониестимулирующий фак-тор и его растворимый рецептор, макрофаг-хемопри-влекающий протеин.…”

Section: '2010unclassified

Endokrinnye mekhanizmy modulyatsii serdechnoydeyatel'nosti u patsientov s khronicheskoyserdechnoy nedostatochnost'yu: rol' gormona rosta

Dedov¹,

Bondarenko²,

Безлепкина³

2010

Obes. metabol.

View full text Add to dashboard Cite

Chronic heart failure (CHF) is a complication of most cardiovascular diseases. Despite of the last achievements in pharmacotherapy, life expectancy in patients with CHF remains to be the lowest, and the risk of sudden death is the highest. The last 20 years stressed the importance of growth hormone role in the development of cardiovascular disease, and its potential in treatment of terminal CHF. This article reviews the most well-known research conducted in this area.

show abstract

LncRNA SLC8A1‐AS1 protects against myocardial damage through activation of cGMP‐PKG signaling pathway by inhibiting SLC8A1 in mice models of myocardial infarction

Guo

Sun

et al. 2018

Journal Cellular Physiology

View full text Add to dashboard Cite

Extensive investigations into long noncoding RNAs (lncRNAs) in various diseases and cancers, including acute myocardial infarction (AMI) have been conducted. The current study aimed to investigate the role of lncRNA solute carrier family 8 member A1 antisense RNA 1 (SLC8A1‐AS1) in myocardial damage by targeting solute carrier family 8 member A1 (SLC8A1) via cyclic guanosine 3′,5′‐monophosphate‐protein kinase G (cGMP‐PKG) signaling pathway in AMI mouse models. Differentially expressed lncRNA in AMI were initially screened and target relationship between lncRNA SLC8A1‐AS1 and SLC8A1 was then verified. Infarct size, levels of inflammatory factors, biochemical indicators, and the positive expression of the SLC8A1 protein in AMI were subsequently determined. The expression of SLC8A1‐AS1, SLC8A1, PKG1, PKG2, atrial natriuretic peptide, and brain natriuretic peptide was detected to assess the effect of SLC8A1‐AS1 on SLC8A1 and cGMP‐PKG. The respective contents of superoxide dismutase, lactate dehydrogenase (LDH), and malondialdehyde (MDA) were detected accordingly. Microarray data GSE66360 provided evidence indicating that SLC8A1‐AS1 was poorly expressed in AMI. SLC8A1 was verified to be a target gene of lncRNA SLC8A1‐AS1. SLC8A1‐AS1 upregulation decreased levels of left ventricular end‐systolic diameter, −dp/ dt max, interleukin 1β (IL‐1β), IL‐6, transforming growth factor α, nitric oxide, inducible nitric‐oxide synthase, endothelial nitric‐oxide synthase, infarct size, LDH activity and MDA content, and increased IL‐10, left ventricular end‐diastolic pressure and + dp/ dt max. Furthermore, the overexpression of SLC8A1‐AS1 was noted to elicit an inhibitory effect on the cGMP‐PKG signaling pathway via SLC8A1. In conclusion, lncRNA SLC8A1‐AS1, by downregulating SLC8A1 and activating the cGMP‐PKG signaling pathway, was observed to alleviate myocardial damage, inhibit the release of proinflammatory factors and reduce infarct size, ultimately protecting against myocardial damage.

show abstract

Effects of growth hormone on circulating cytokine network, and left ventricular contractile performance and geometry in patients with idiopathic dilated cardiomyopathy

Cited by 78 publications

References 42 publications

Cardiovascular Disease and Risk Factors: The Role of Growth Hormone

Cardiovascular Disease and Risk Factors: The Role of Growth Hormone

Endokrinnye mekhanizmy modulyatsii serdechnoydeyatel'nosti u patsientov s khronicheskoyserdechnoy nedostatochnost'yu: rol' gormona rosta

LncRNA SLC8A1‐AS1 protects against myocardial damage through activation of cGMP‐PKG signaling pathway by inhibiting SLC8A1 in mice models of myocardial infarction

Contact Info

Product

Resources

About